Evidence map›Paper›PMID 40832784›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

ABCA7 deletion lowers age at onset of Alzheimer's disease and interacts with APOE ε4 synergistically in African-ancestry populations.

Bilcag Akgun, Alexander V Gulyayev, Motunrayo Coker, Kara L Hamilton-Nelson, Oladotun Olalusi, Larry D Adams, Kazeem Akinwande, Patrice G Whitehead, Samuel Diala, Mayowa Ogunronbi and 35 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Disrupted lipid homeostasis as a pathogenic mechanism in ABCA7-associated Alzheimer's disease risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Bilcag AkgunJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Alexander V GulyayevJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Motunrayo CokerNeuroscience and Ageing Research Unit, Institute for Advanced Medical Research & Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Kara L Hamilton-NelsonJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Oladotun OlalusiNeuroscience and Ageing Research Unit, Institute for Advanced Medical Research & Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Larry D AdamsJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Kazeem AkinwandeNeuroscience and Ageing Research Unit, Institute for Advanced Medical Research & Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Patrice G WhiteheadJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Samuel DialaNeuroscience and Ageing Research Unit, Institute for Advanced Medical Research & Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Mayowa OgunronbiNeuroscience and Ageing Research Unit, Institute for Advanced Medical Research & Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Renee A LauxDepartment of Population & Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Albert AkpaluDepartment of Medicine, University of Ghana Medical School/Korle Bu Teaching Hospital, Accra, Ghana.
Takiyah D StarksDepartment of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Fred S SarfoDepartment of Medicine, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana.
Jenny ChavezGertrude H. Sergievsky Center, Taub Institute for Research on the Aging Brain, Departments of Neurology, Psychiatry, and Epidemiology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Kamada LwereMakerere University College of Health Sciences, Kampala, Uganda.
Gary W BeechamDepartment of Biostatistics and Data Science, Wake Forest School University of Medicine, Winston-Salem, North Carolina, USA.
Joshua O AkinyemiDepartment of Epidemiology and Medical Statistics, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Reginald ObiakoDepartment of Medicine, Ahmadu Bello University, Zaria, Nigeria.
David NdeteiAfrica Mental Health Research and Training Foundation/Department of Psychiatry, University of Nairobi, Nairobi, Kenya.
Allison Caban-HoltDepartment of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Biniyam AyeleJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Paula OgrockiDepartment of Neurology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Anthony J GriswoldJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Andrew F ZamanJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Pedro R MenaJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Izri M MartinezJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Susan H BlantonJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Njideka OkubadejoDepartment of Medicine, College of Medicine, University of Lagos, Lagos, Nigeria.
Albertino DamascenoFaculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.
Rajesh KalariaTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Michael L CuccaroJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Katalina F McInerneyDepartment of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA.
African Dementia Consortium (AfDC)
Alzheimer's Disease Sequencing Project (ADSP)
William S BushDepartment of Population & Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Brian W KunkleJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Adesola OgunniyiNeuroscience and Ageing Research Unit, Institute for Advanced Medical Research & Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Jeffery M VanceJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Rufus O AkinyemiNeuroscience and Ageing Research Unit, Institute for Advanced Medical Research & Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Jonathan L HainesDepartment of Population & Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Christiane ReitzGertrude H. Sergievsky Center, Taub Institute for Research on the Aging Brain, Departments of Neurology, Psychiatry, and Epidemiology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Goldie S ByrdDepartment of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Farid RajabliJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Margaret A Pericak-VanceJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.

Funding

Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD-ADSP)U19AG074865 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GOLDIE S. BYRD, William S Bush · 2022 to 2026
$55.3M
Additional Sequencing for the Alzheimer Disease Sequencing Project (ADSP) the Follow-Up Study (FUS), The Global Population InitiativeU01AG076482 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Clifton L Dalgard, ANTHONY JOHN GRISWOLD · 2022 to 2026
$26.9M
The Origins of Alzheimer Disease in African AmericansR01AG072547 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Rufus Olusola Akinyemi, GOLDIE S. BYRD · 2022 to 2026
$26.1M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Characterizing the Genetic Risk for Alzheimer Disease in African and Admixed African-American AncestriesU01AG084545 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GOLDIE S. BYRD, ANTHONY JOHN GRISWOLD · 2024 to 2026
$14.9M
National Institute on Aging of National Institutes of HealthNIA NIH HHS P30 AG072947NIA NIH HHS R01 AG072547NIA NIH HHS R01AG072547NIA NIH HHS U01 AG076482NIA NIH HHS U01AG076482NIA NIH HHS U01 AG084545NIA NIH HHS U01AG084545NIA NIH HHS U19 AG074865NIA NIH HHS U19AG074865
6 · The paper itself

Abstract

introductionApolipoprotein E (APOE) and ABCA7 genes are among the strongest heritable risk factors for Alzheimer's disease (AD) in African-ancestry (AA) populations. APOE 𝜀4 affects both risk and age at onset (AAO), with lower risk in AA populations. This study evaluates the independent and interactive effects of the AA-specific ABCA7 frameshift deletion and APOE 𝜀4 allele on AAO.

methodsWe analyzed 3510 AA individuals, including AD cases and controls. Cox regression models assessed the effects of ABCA7 deletion, APOE genotypes, and their interactive influence on AAO.

resultsAPOE ε3/ε4 carriers with the ABCA7 deletion had a significantly shorter survival compared to ε3/ε4 carriers without the deletion. No significant differences were found between deletion carriers and non-carriers with APOE ε3/ε3 or ε4/ε4 genotypes. DISCUSSION: Our study showed that the ABCA7 deletion lowered the AAO of AD in APOE ε3/ε4 carriers from AA populations. These findings suggest that the AA-specific ABCA7 deletion and the APOE ε4 allele have synergistic effects on AAO. HIGHLIGHTS: AA-specific ABCA7 deletion lowers AAO of AD in APOE ε3/ε4 carriers from AA populations. Findings suggest an interaction between ABCA7 deletion and APOE ε4 on AAO. APOE ε4 has a strong, dose-dependent effect on AAO of AD in AA individuals. ABCA7 deletion impact on AAO of AD is stronger in females with APOE ε3/ε4.

Indexed as

Alzheimer DiseaseApolipoprotein E4ATP-Binding Cassette TransportersBlack or African AmericanAgedAged, 80 and overAge of OnsetFemaleGene DeletionGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedABCA7 protein, humanApolipoprotein E4ATP-Binding Cassette TransportersABCA7African ancestryage at onsetAlzheimer's diseaseAPOE

Identifiers

PMID40832784
PMCPMC12365657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.